Medtronic to cut up to 900 jobs:
This article was originally published in Clinica
Medtronic said in a regulatory filing that it could lay off up to 900 employees, after the company was severely affected by a slowdown in the US implantable cardioverter defibrillator market. The Fridley, Minneapolis-based firm had previously announced that it was to cut 550 jobs (see Clinica No 1262, p 13) but has now upped this figure to include extra early retirements, voluntary departures and layoffs. As of July, 349 jobs had already been eliminated - the company incurred a $14m charge related to compensation expenses, which will be deducted from earnings for the first quarter of 2008.
You may also be interested in...
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.